Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price dropped 13.7% during mid-day trading on Thursday. The stock traded as low as GBX 1.21 and last traded at GBX 1.21. Approximately 8,691,818 shares changed hands during trading, an increase of 1,548% from the average session volume of 527,447 shares. The stock had previously closed at GBX 1.40.
Allergy Therapeutics Stock Performance
The stock has a market cap of £71.30 million, a price-to-earnings ratio of -1.16, a P/E/G ratio of -30.70 and a beta of 0.83. The company has a current ratio of 2.29, a quick ratio of 1.48 and a debt-to-equity ratio of -646.31. The firm has a fifty day simple moving average of GBX 3.73 and a 200-day simple moving average of GBX 7.33.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
